Form 4: Oric Pharmaceuticals Director Acquires 35,000 Stock Options

Director Mardi Dier acquired 35,000 stock options in Oric Pharmaceuticals, vesting monthly over the next year.

Summary

• Mardi Dier, a director at Oric Pharmaceuticals, acquired 35,000 stock options on January 2, 2025.
• The options have an exercise price of $8.26 per share.
• The options vest monthly, with 1/12th of the shares vesting on each one-month anniversary of January 2, 2025.
• The options expire on January 1, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard insider transaction, which is generally neutral to positive. The director's acquisition of options suggests confidence in the company's future.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard transaction for a director of a public company, often used as part of their compensation package and to align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the pharmaceutical industry, aligning their interests with the long-term success of the company.
• The vesting schedule of 1/12th per month is a typical vesting schedule for stock options.

Stakeholder Impact

• The stock option grant could positively impact shareholder sentiment, as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, insider trading, director, Mardi Dier, Oric Pharmaceuticals, ORIC, equity